Navigation Links
Jentadueto® (linagliptin/metformin hydrochloride) tablets recommended for approval in the treatment of adults with type 2 diabetes in Europe
Date:5/29/2012

RIDGEFIELD, Conn. and INDIANAPOLIS, May 29, 2012 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced they have received a positive opinion from the European Medicines Agency's (EMA) medicinal committee recommending approval of Jentadueto® (linagliptin/metformin hydrochloride) tablets, a medicine combining the DPP-4 inhibitor, linagliptin (the active ingredient in Tradjenta® tablets, marketed under the trade name Trajenta® in Europe) and metformin in a single tablet taken twice daily.(1)

The EMA's Committee for Medicinal Products for Human Use (CHMP) recommended the approval of JENTADUETO for use alongside diet and exercise to improve glycemic control in adults with type 2 diabetes who are inadequately controlled on their maximally tolerated dose of metformin alone or those already being treated with the combination of linagliptin and metformin. If approved by the European Commission, JENTADUETO will provide a new, single-tablet treatment option, taken twice daily, for adults with type 2 diabetes who need to improve control of their blood glucose.(2)

"The CHMP positive opinion for JENTADUETO marks another important regulatory milestone for the Boehringer Ingelheim and Eli Lilly and Company worldwide diabetes alliance, extending our commitment to bringing new medicines to those patients who need them," said Prof. Klaus Dugi, Corporate Senior Vice President Medicine, Boehringer Ingelheim. "Around the world, many people with type 2 diabetes require more than one treatment to adequately manage their blood sugar. By combining two important diabetes medicines in a single tablet, we believe that JENTADUETO will provide people with type 2 diabetes another way of improving control of their blood sugar."

JENTADUETO was approved by the U.S. Food and Drug Administration (FDA) in January 2012 as a prescription medicine used along with diet and exercise to improve glycemic control i
'/>"/>

SOURCE Eli Lilly and Company; Boehringer Ingelheim
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Boehringer Ingelheim and Lillys new oral type 2 diabetes treatment for adults, Jentadueto™ (linagliptin/metformin hydrochloride) tablets, now available in U.S. pharmacies
2. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
3. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
4. Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session
5. Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting
6. Shionogi Inc. Announces Commercial Availability of KAPVAY™ (clonidine hydrochloride) Extended-Release Tablets for the Treatment of ADHD
7. Shionogi Inc. Announces Publication of Data in Pediatrics Demonstrating Efficacy of KAPVAY™ (clonidine hydrochloride) Extended-Release Tablets as Add-On Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents
8. Breckenridge Pharmaceutical Announces Settlement of Actos® (Pioglitazone Hydrochloride) Patent Litigation
9. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
10. New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR(R) (zolpidem tartrate extended-release) Tablets CIV
11. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... , May 22, 2015  China Nepstar Chain Drugstore ... leading retail drugstore chain in China ... today announced the resignation of Mr. Fuxiang Zhang ... reasons, effective immediately. Ms. Rebecca Yingnan Zhang ... Company,s board of directors, effective immediately. Meanwhile, Ms. Zhang ...
(Date:5/21/2015)... Research and Markets ... of the "Arthroscopy Devices Markets Worldwide" ... http://photos.prnewswire.com/prnh/20130307/600769) , ,The purpose of this report ... market for Arthroscopy Devices. The report discusses ... market for these products. , ,Product - ...
(Date:5/21/2015)... , 21. Mai 2015 /PRNewswire/ ... DPRX ), ein Unternehmen für Arzneimittel ... die Entwicklung und Vermarktung von Locilex® ... kündigte heute eine wissenschaftliche Posterpräsentation an, ... des Unternehmens vorstellt, OneStep-1 und OneStep-2, ...
Breaking Medicine Technology:China Nepstar Chain Drugstore Ltd. Announces Management Change and New Director Appointment 2China Nepstar Chain Drugstore Ltd. Announces Management Change and New Director Appointment 3Analysing Arthroscopy Devices Markets Worldwide 2014-2020 2Analysing Arthroscopy Devices Markets Worldwide 2014-2020 3Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 2Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 3Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 4Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 5Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 6Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 7
... THE OHIO STATE UNIVERSITY ... CENTER JOINS PHASE III TRIAL FOR METASTATIC MELANOMA ... (Nasdaq: DCTH ) announced today that The Ohio ... Research Institute has joined Delcath,s Phase III clinical trial for the treatment ...
... online this week in the Journal of Clinical ... selective estrogen receptor modulator (SERM) being developed by Eli ... increased lumbar spine and total hip bone mineral density ... mass, versus placebo.In addition, arzoxifene, dosed at 20 mg/day, ...
Cached Medicine Technology:Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM) 2Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM) 3Newly Published Phase III Study Shows Arzoxifene Significantly Increased Bone Mineral Density 2Newly Published Phase III Study Shows Arzoxifene Significantly Increased Bone Mineral Density 3Newly Published Phase III Study Shows Arzoxifene Significantly Increased Bone Mineral Density 4
(Date:5/22/2015)... 22, 2015 Pioneer Millworks, the largest ... forefront of designing with reclaimed wood, introducing their latest ... Angeles, California. Their newest offerings, Vat 35, Reclaimed ... and color to America's largest design event. , “Designers, ... each show, anxious to see and feel the variety ...
(Date:5/22/2015)... 2015 River Valley Health Partners (RVHP) ... health system’s Chief Financial Officer (CFO), will be leaving ... as the company CFO since 2011. , The Board ... the health system as CFO. Wesley will oversee the ... the Board of Trustees conducts a formal search for ...
(Date:5/22/2015)... Pa. (PRWEB) May 22, 2015 Omar ... been selected to participate in the 2015 Congress of ... is described as a gathering of “America’s highest achieving ... new areas of healthcare, set new goals and learn ... include a live surgery, during which we can ask ...
(Date:5/22/2015)... “It’s like learning an new ... Vice President of Clinical Operations/Education and Training at ... impacts how care is coded and reimbursed.” , ... care reimbursement, operations and compliance consulting, as well ... launches a new series of day-long seminars on ...
(Date:5/22/2015)... May 22, 2015 Coordinating care ... difficult process. Historically providers have not been reimbursed ... Starting in 2015, Medicare has paved the way ... Thanks to the launch of Oculus Health ... health systems using the platform will now be ...
Breaking Medicine News(10 mins):Health News:Pioneer Millworks to Reveal New Design Trends with Reclaimed Wood at Dwell on Design in LA 2Health News:Pioneer Millworks to Reveal New Design Trends with Reclaimed Wood at Dwell on Design in LA 3Health News:River Valley Health Partners Announces CFO Transition, Appointment of Interim CFO 2Health News:Milton Hershey School Student Chosen for Congress of Future Medical Leaders 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 3Health News:Oculus Health Care Coordination Platform Officially Launched 2Health News:Oculus Health Care Coordination Platform Officially Launched 3Health News:Oculus Health Care Coordination Platform Officially Launched 4
... (NYSE: LNC ) today announced the introduction of ... disability (LTD) insurance product. Lincoln already offers one of the ... the addition of this optional benefit -- employers now have ... cost concerns as they try to return to work. (Logo: ...
... bacteria that threaten those with COPD, study says , , ... smoking help cause chronic obstructive pulmonary disease (COPD), it ... can worsen the disease, Canadian researchers report. , The ... how smokers with COPD are treated, the experts said. ...
... ETS EXPOSURE , Environmental tobacco smoke (ETS) exposure ... However, a new study shows that reducing exposure ... Alabama researchers followed 240 children with asthma who ... therapy. No smoking cessation counseling or ETS exposure ...
... RAC Credential Focuses on General Scope of Regulatory ... The Regulatory Affairs Professionals Society (RAPS) has ... RAC General Scope (GS). The RAC (GS) credential ... practice of regulatory professionals in the healthcare product ...
... DETROIT, April 7 The Detroit Wayne County ... enrollment service that will expedite the screening and ... called HelpEngen(TM), was developed by TriHealix, a health ... enables health care providers to connect uninsured patients ...
... http://www.HealthGuru.com ) was the fastest growing health site on the web over ... of the few health sites with more video views than unique visitors ... ... 7, 2009 -- According to the comScore, Inc. February rankings, Health Guru ...
Cached Medicine News:Health News:Lincoln Financial Group Announces Family Care Reimbursement Benefit Rider on LTD Policies 2Health News:Lincoln Financial Group Announces Family Care Reimbursement Benefit Rider on LTD Policies 3Health News:Lincoln Financial Group Announces Family Care Reimbursement Benefit Rider on LTD Policies 4Health News:Smoking Ups Infection Risk for Lung Disease Patients 2Health News:Journal Chest: April news briefs 2Health News:RAPS Offers New International Regulatory Affairs Certification - RAC (GS) 2Health News:Health Authority Offers Expedient, Web-Based Medicaid Enrollment Service 2Health News:Health Authority Offers Expedient, Web-Based Medicaid Enrollment Service 3Health News:Web's Fastest Growing Health Site is a Video Site 2Health News:Web's Fastest Growing Health Site is a Video Site 3
... pulsed radiofrequncy current, the Valleylab ... heats and ablates large volumes ... minimal time., RF alblation procedures ... surgery, percutaneously, or laparoscopically, depending ...
... is a biologically based adhesive supplied ... system consisting of a liquid substrate ... of internal bleeding. When ... on to a prepared wound and ...
... (Human) achieves a secure clot, targeted to ... for hemostasis is needed, when control of ... ligature, and cautery, is ineffective or impractical., ... formulation of human Biologically Active Component (BAC) ...
... BD Cell-Tak™ Cell and Tissue Adhesive ... from Mytilus edulis (marine mussel). These proteins ... secreted by the mussel to anchor itself ... BD Cell-Tak Cell and Tissue Adhesive is ...
Medicine Products: